Soligenix (Nasdaq: SNGX) announced that the European Commission granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet’s Disease. The designation follows a positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
In the EU, orphan drug designation provides a 10-year period of marketing exclusivity following product approval, along with incentives including protocol assistance from the EMA and direct access to the centralized authorization procedure. SGX945 previously received orphan drug designation and Fast Track designation from the U.S. Food and Drug Administration (FDA) for Behçet’s Disease, as well as Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).
Dusquetide, the active ingredient in SGX945, is a synthetic peptide classified as an innate defense regulator (IDR). Rather than targeting a single receptor, it modulates innate immune system responses toward anti-inflammatory and tissue-healing pathways. The EMA designation was granted following review of Phase IIa clinical results in eight patients with Behçet’s Disease. In that open-label study, the primary endpoint — area under the curve (AUC) of the mean number of oral ulcers versus time — showed a 40% improvement relative to the placebo arm from the Phase III apremilast registration study after four weeks of treatment. The improvement was sustained at 32% through a four-week follow-up period after treatment cessation. No treatment-related adverse events were reported. No active or recruiting clinical trials for dusquetide in Behçet’s Disease are currently listed in major public registries.
The only approved therapy for oral ulcers in Behçet’s Disease is apremilast (Otezla), a phosphodiesterase 4 (PDE4) inhibitor marketed by Amgen. Apremilast requires continuous administration and carries a side-effect profile that includes diarrhea (41% of patients), nausea (19%), and headache (14%) based on its registration data. Dusquetide operates through a distinct mechanism — innate immune modulation rather than PDE4 inhibition — and the Phase IIa data showed none of these gastrointestinal or neurological adverse events. The current treatment landscape otherwise relies on corticosteroids, immunosuppressants such as azathioprine and cyclosporine, and TNF inhibitors including infliximab and adalimumab for severe or refractory cases. Apremilast remains the only specifically approved drug for oral ulcers in Behçet’s disease.
Behçet’s disease affects an estimated 18,000 people in the US, over 50,000 in Europe, and up to 1 million worldwide, with prevalence concentrated along the historical Silk Road region. The condition meets EU orphan disease criteria at fewer than 5 in 10,000 persons.